This inventor holds 5 USPTO granted patents. Top assignee: Aprinoia Therapeutics Limited. Active years: 2021-2025.
Company Filing History:
Years Active: 2021-2025
Title: The Innovative Contributions of Ming-Kuei Jang
Introduction
Ming-Kuei Jang is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of neurodegenerative disease research, holding a total of five patents. His work focuses on developing compounds that target specific protein aggregates associated with various neurodegenerative conditions.
Latest Patents
Among his latest patents are "Compounds for degrading alpha-synuclein aggregates and uses thereof." This patent provides compounds, compositions, and methods useful for treating neurodegenerative diseases, particularly synucleinopathies. Another notable patent is "Compounds for degrading Tau protein aggregates and uses thereof." This disclosure presents novel compounds for degrading Tau protein aggregates, along with their pharmaceutical acceptable salts, enantiomers, and other derivatives. These compounds are aimed at aiding in the treatment of tauopathies.
Career Highlights
Ming-Kuei Jang is currently associated with Aprinoia Therapeutics Limited, where he continues to advance his research and innovations. His work has been instrumental in developing therapeutic strategies for complex neurodegenerative diseases.
Collaborations
He collaborates with esteemed colleagues such as Yih-Shyan Lin and Paul Tempest, contributing to a dynamic research environment focused on innovative solutions for neurodegenerative disorders.
Conclusion
Ming-Kuei Jang's contributions to the field of neurodegenerative disease research are noteworthy. His innovative patents and collaborative efforts position him as a key figure in the ongoing fight against these challenging conditions.